Claims for Patent: 4,798,800

Summary for Patent: 4,798,800

Title:	Process for isolating human globular domain NC1 of basal membrane collagen from human tissue
Abstract:	The present invention provides human characterized by a molecular weight of about 170,000 Dalton, a hexameric structure with monomeric subunits with a molecular weight of about 28,000 Dalton and a carbohydrate content of about 2%. The present invention provides a process for obtaining and purifying globular domain NC1 of basal membrane collagen, wherein human or animal tissue is subjected to a first limiting treatment with bacterial collagenase, the degradation products obtained are separated from non-collagen proteins by chromatography on a weakly basic anion exchanger, the collagen degradation products are then subjected to a second collagenase digestion at an elevated temperature and the globular domain NC1 is purified by molecular sieve fractionation. Furthermore, the present invention is concerned with the use of this for the determination in body fluids in the case of the use of their antibodies, as well as far the detection of antibodies directed thereagainst in body fluids.
Inventor(s):	Timpl; Rupert (Gauting, DE), Brocks; Dietrich (Hunfelden, DE)
Assignee:	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften e.V. (Gottingen, DE)
Application Number:	06/664,538
Patent Claims:	1. A process for isolating and purifying globular domain NCl from basal membrane collagen comprising extracting globular domain NCl containing tissue with guanidine hydrochloride to obtain a globular NCl containing extract treating said extract with bacterial collagenase to degrade collagen fragments in said extract separating the degradation products obtained from non-collagenous proteins by chromatography on a weakly basic anion exchanger, treating the collagen degradation products a second time with collagenase at an elevated temperature and purifying the globular domain NCl by molecular sieve fractionation. 2. The process of claim 1, wherein said tissue is homogenised in a salt-containing buffer solution before subjecting to the first treatment. 3. The process of claim 1, wherein said tissue is derived from tissue, human placenta tissue, human kidney tissue, human lung tissue bovine aorta tissue or EHS sarcoma tissue. 4. The process of claim 1, wherein the first collagenase treatment is carried out at a temperature of from 15.degree. to 25.degree. C. 5. The process of claim 1, wherein the second collagenase digestion is carried out at a temperature of from 30.degree. to 45.degree. C. 6. The process of claim 1, wherein said anion exchanger is a diethylaminoethanol group-modified carbohydrate. 7. The process of claim 1, wherein the first collagenase treatment is carried out at a temperature of from 15.degree. to 25.degree. C., the second collagenase treatment is carried out at a temperature of from 30.degree. to 45.degree. C. and said anion exchanger is a diethylaminoethanol group-modified carbohydrate.

Details for Patent 4,798,800

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2006-01-17